Fintel reports that on September 5, 2023, B. Riley Securities reiterated coverage of Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral recommendation.Fintel reports that on September 5, 2023, B. Riley Securities reiterated coverage of Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral recommendation.
